The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer

• Published in: Future oncology (London, England) England), 2024, Vol.20 (32), p.2457-2466
• Main Authors: Fjermeros, Kamilla, Ghannoum, Salim, Geisler, Stephanie B, Bhargava, Sameer, Tahiri, Andliena, Klajic, Jovana, Lüders, Torben, Fongård, Marie, Nawaz, Meh Sameen, Bosnjak-Olsen, Tatjana, Buvarp, Unn-Cathrin Edvardsen, Rosenskiold, Aino Katri Johanna, Nguyen, Nam Thi, Sletbak, Tone Tysko, Seyedzadeh, Manouchehr, Selsås, Knut, Porojnicu, Alina Carmen, Skjerven, Helle Kristine, Hovda, Tone, Sahlberg, Kristine Kleivi, Torland, Lilly Anne, Lyngra, Marianne, Hammarström, Clara Louise, Hönigsperger, Elma Bahonjic, Noone, John Christopher, Mathiassen, Silje, Hurtado, Antoni, Goel, Shom, Koff, Andrew, Tekpli, Xavier, Kristensen, Vessela N, Geisler, Jürgen
• Format: Article
• Language: English
• Subjects: Adult; Aminopyridines - administration & dosage; Aminopyridines - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Female; Humans; Letrozole - administration & dosage; Letrozole - therapeutic use; Method; Middle Aged; Neoadjuvant Therapy - methods; Purines - administration & dosage; Purines - therapeutic use; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - metabolism; Treatment Outcome
• ISSN: 1479-6694; 1744-8301; 1744-8301
• DOI: 10.1080/14796694.2024.2377531

Chemotherapy is used as neoadjuvant therapy for all subgroups of breast cancer, including ER-positive, and HER2-negative cases. However, studies have suggested that using aromatase inhibitors combined with CDK4/6-inhibitors might be an appropriate alternative in selected patients. Thus, the NEOLETRIB trial evaluates the response of ER-positive, HER2-negative luminal A/B breast cancer to the combination of letrozole and ribociclib in the neoadjuvant setting. Comprehensive molecular biology procedures, including sequential single-cell RNA-sequencing of tumor biopsies, are performed during 6 months of treatment with extensive biobanking of blood samples, tumor biopsies and gut microbiome specimens. Our findings will hopefully contribute to an improved selection of patients who may benefit from this drug combination and give new insights into the intra-tumoral changes during this treatment. NCT05163106 (ClinicalTrials.gov).